Researchers at Yale University have published early findings suggesting distinct immune patterns in a small group of people experiencing persistent symptoms after receiving COVID-19 mRNA vaccines. Dubbed “post-vaccination syndrome” (PVS), the condition involves complaints like severe fatigue, brain fog, dizziness, tinnitus, and exercise intolerance. While the study offers intriguing clues, experts—including the authors—stress it remains preliminary and far from definitive. Here's a clear, balanced look at what we know so far.
What the Yale Researchers Found
In February 2025, a team led by immunologist Dr. Akiko Iwasaki and cardiologist Dr. Harlan Krumholz released a preprint analyzing data from Yale’s LISTEN Study (Listen to Immune, Symptom, and Treatment Experiences Now). They compared blood samples and reported symptoms from 42 individuals who described ongoing health issues starting soon after COVID-19 vaccination with 22 healthy vaccinated controls.
Participants with PVS often reported symptoms appearing within days to weeks of their shot—most commonly debilitating fatigue, exercise intolerance, brain fog, neuropathy, dizziness, tinnitus, and insomnia. Many described these issues as life-altering and persisting for months or years.
Key biological observations included:
- Altered immune cell profiles: lower levels of certain effector CD4 T cells and higher TNF-secreting CD8 T cells in the PVS group.
- Signs of Epstein-Barr virus (EBV) reactivation—a common dormant herpesvirus that, when reawakened, can trigger flu-like symptoms, swollen lymph nodes, and neurological issues.
- Detectable SARS-CoV-2 spike protein in the blood of many PVS participants, sometimes lingering for hundreds of days (up to 709 days in isolated cases). This finding surprised researchers, as spike protein from mRNA vaccines typically clears quickly.
“That was surprising, to find spike protein in circulation at such a late time point,” said Dr. Iwasaki. “We don’t know if the level of spike protein is causing the chronic symptoms, because there were other participants with PVS who didn’t have any measurable spike protein. But it could be one mechanism underlying this syndrome.”
Importantly, not every person with reported PVS showed measurable spike protein, and lower anti-spike antibody levels in the group were linked to fewer subsequent vaccine doses.
Context and Cautions from the Researchers
The authors repeatedly emphasize that this is early-stage work. The sample size is small, the study is not yet peer-reviewed, and findings need replication in larger, more diverse groups.
“This work is still in its early stages, and we need to validate these findings,” Dr. Iwasaki noted. “But this is giving us some hope that there may be something that we can use for diagnosis and treatment of PVS down the road.”
They also highlight potential overlapping mechanisms with long COVID, where persistent spike protein, viral reservoirs, immune dysregulation, and EBV reactivation have likewise been observed in some patients.
Thousands of individuals have self-reported vaccine-related injuries since the 2021 rollout. However, fragmented healthcare systems and the challenge of distinguishing rare side effects from coincidental illnesses make causation difficult to establish. Large-scale studies have generally confirmed that serious adverse events remain uncommon, while vaccines have prevented millions of severe COVID-19 cases and reduced long COVID risk overall.
Latest Developments in PVS Research (as of early 2026)
In July 2025, Dr. Iwasaki joined the SPEAR Study Group (Spike Protein Elimination and Recovery), collaborating on explorations of monoclonal antibodies to target persistent spike protein in both long COVID and PVS. This reflects growing scientific interest in possible therapeutic avenues, though no treatments are approved or proven yet.
Read the July 2025 announcement from Invivyd.
The original preprint remains the core immunological analysis:
Yale’s official summary provides accessible context:
The LISTEN Study continues recruiting participants to deepen understanding of both long COVID and PVS.
Broader Implications and Ongoing Debate
While PVS appears exceedingly rare, the Yale work has fueled discussion about rare post-vaccination effects and the need for better surveillance. Some see parallels to other vaccine-related conditions or post-viral syndromes; others caution against overinterpreting preliminary data amid polarized views on COVID-19 vaccines.
Independent reviews note that vaccines dramatically lowered severe disease, hospitalization, and death rates during the pandemic. Any potential rare syndrome must be weighed against those proven population-level benefits.
Future steps include larger validation studies, determining PVS prevalence, identifying at-risk groups, and testing whether interventions (like clearing persistent antigens) could help affected individuals.
Original Source Inspiration: Daily Mail article (February 2025) – Yale scientists link Covid vaccines to alarming new syndrome. Content expanded and updated with direct Yale and preprint sources for accuracy and neutrality.